PL4232151T3 - Zastosowanie przeciwciała przeciwko pro/latentnej miostatynie w leczeniu rdzeniowego zaniku mięśni - Google Patents

Zastosowanie przeciwciała przeciwko pro/latentnej miostatynie w leczeniu rdzeniowego zaniku mięśni

Info

Publication number
PL4232151T3
PL4232151T3 PL21807468.0T PL21807468T PL4232151T3 PL 4232151 T3 PL4232151 T3 PL 4232151T3 PL 21807468 T PL21807468 T PL 21807468T PL 4232151 T3 PL4232151 T3 PL 4232151T3
Authority
PL
Poland
Prior art keywords
pro
muscular atrophy
spinal muscular
myostatin antibody
latent myostatin
Prior art date
Application number
PL21807468.0T
Other languages
English (en)
Polish (pl)
Inventor
George NOMIKOS
Guochen SONG
Ryan Iarrobino
Yung CHYUNG
Original Assignee
Scholar Rock, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scholar Rock, Inc. filed Critical Scholar Rock, Inc.
Publication of PL4232151T3 publication Critical patent/PL4232151T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL21807468.0T 2020-10-26 2021-10-25 Zastosowanie przeciwciała przeciwko pro/latentnej miostatynie w leczeniu rdzeniowego zaniku mięśni PL4232151T3 (pl)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202063105850P 2020-10-26 2020-10-26
US202063106172P 2020-10-27 2020-10-27
US202163200955P 2021-04-05 2021-04-05
US202163201157P 2021-04-15 2021-04-15
US202163202317P 2021-06-06 2021-06-06
US202163202372P 2021-06-08 2021-06-08
US202163202900P 2021-06-29 2021-06-29
US202163260725P 2021-08-30 2021-08-30
US202163261398P 2021-09-20 2021-09-20
PCT/US2021/056517 WO2022093724A1 (en) 2020-10-26 2021-10-25 Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy

Publications (1)

Publication Number Publication Date
PL4232151T3 true PL4232151T3 (pl) 2026-02-23

Family

ID=78622120

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21807468.0T PL4232151T3 (pl) 2020-10-26 2021-10-25 Zastosowanie przeciwciała przeciwko pro/latentnej miostatynie w leczeniu rdzeniowego zaniku mięśni

Country Status (13)

Country Link
US (1) US20240002490A1 (enExample)
EP (2) EP4729069A1 (enExample)
JP (1) JP2023549455A (enExample)
KR (1) KR20230095998A (enExample)
CN (1) CN116390756A (enExample)
AU (1) AU2021369471A1 (enExample)
CA (1) CA3193909A1 (enExample)
ES (1) ES3058087T3 (enExample)
IL (1) IL302132A (enExample)
MX (1) MX2023004763A (enExample)
PL (1) PL4232151T3 (enExample)
TW (1) TW202233234A (enExample)
WO (1) WO2022093724A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20211081T1 (hr) 2015-09-15 2021-10-15 Scholar Rock, Inc. Anti-pro/latentna miostatinska protutijela i njihove uporabe
DK4518970T3 (da) 2022-05-04 2026-04-07 Scholar Rock Inc Anvendelse af myostatinhæmmer til behandling af spinal muskelatrofi
EP4638496A1 (en) 2022-12-22 2025-10-29 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation
WO2026076383A1 (en) 2024-10-06 2026-04-09 Scholar Rock, Inc. Use of myostatin inhibitor for treating spinal muscular atrophy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040044063A1 (en) 2002-05-31 2004-03-04 Brent Stockwell SMA therapy and cell based assay for identifying therapies
JP2010523684A (ja) 2007-04-12 2010-07-15 パラテック ファーマシューティカルズ インコーポレイテッド テトラサイクリン化合物を用いる、脊髄筋委縮症を治療するための方法
HRP20211081T1 (hr) 2015-09-15 2021-10-15 Scholar Rock, Inc. Anti-pro/latentna miostatinska protutijela i njihove uporabe
NZ789269A (en) 2016-06-13 2026-01-30 Scholar Rock Inc Use of myostatin inhibitors and combination therapies

Also Published As

Publication number Publication date
IL302132A (en) 2023-06-01
US20240002490A1 (en) 2024-01-04
AU2021369471A1 (en) 2023-06-15
CA3193909A1 (en) 2022-05-05
TW202233234A (zh) 2022-09-01
AU2021369471A9 (en) 2024-02-08
KR20230095998A (ko) 2023-06-29
EP4232151A1 (en) 2023-08-30
EP4729069A1 (en) 2026-04-22
CN116390756A (zh) 2023-07-04
MX2023004763A (es) 2023-05-09
EP4232151B1 (en) 2025-10-22
JP2023549455A (ja) 2023-11-27
ES3058087T3 (en) 2026-03-06
WO2022093724A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
PL4232151T3 (pl) Zastosowanie przeciwciała przeciwko pro/latentnej miostatynie w leczeniu rdzeniowego zaniku mięśni
IL276180A (en) Methods for treating spinal muscular atrophy
IL277215A (en) Use of anti-IL-36R antibodies to treat generalized purulent urticaria
LT4518970T (lt) Miostatino inhibitoriaus panaudojimas spinalinės raumenų atrofijos gydymui
IL262830A (en) Preparations and methods for the treatment of spinal muscular atrophy
IL289745A (en) Methods for treating or preventing spinal muscular atrophy
GB201917920D0 (en) Material-based x-ray image enhancement
IL284480A (en) Preparations and methods for the treatment of primary ciliary movement disorder
PT3506901T (pt) Utilização de ácido quinurénico no tratamento da atrofia muscular
ZA202107077B (en) Anti-cd6 antibody compositions and methods for treating lupus
IL276786A (en) Compounds and compositions for the treatment of muscular disorders and bone disorders
PL4125911T3 (pl) Obicetrapib do leczenia otępień
HK40100646B (zh) 抗前肌生成抑制蛋白/潜伏性肌肉生成抑制蛋白抗体用於治疗脊髓性肌肉萎缩的用途
HK40100646A (en) Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy
EP4140498A4 (en) Method and drug for treating spinal muscular atrophy
EP4387622C0 (en) HALOPERIDOL FOR USE IN THE TREATMENT OF SPINAL MUSCULAR ATROPHY
ZA202203442B (en) Oil-based latent resin and preparation method and use thereof
EP4179093A4 (en) COMPOSITIONS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY
IL308045A (en) Treatment of lupus nephritis using antibuffer antibodies
IL286994A (en) A method for the treatment and prevention of bone and joint infections
GB202010383D0 (en) Legalisation of documents
EP3950707A4 (en) COMPOSITION COMPRISING LRRD2 SLIT3 COUPLED TO ALBUMIN FOR THE PREVENTION OR TREATMENT OF A MUSCLE DISEASE
IL326452A (en) A new preparation for the treatment of spinal muscular atrophy
GB202113702D0 (en) Apparatus for the disposal of faeces
HK40070509A (en) Methods of treating or preventing spinal muscular atrophy